MARC details
| 000 -LEADER |
|---|
| fixed length control field |
01853nam a2200277Ia 4500 |
| 000 - LEADER |
|---|
| fixed length control field |
03226naaa 00661uu |
| 001 - CONTROL NUMBER |
|---|
| control field |
https://directory.doabooks.org/handle/20.500.12854/69367 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20211222133947.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
211013s9999 xx 000 0 und d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9783039435852 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.3390/books978-3-03943-586-9 |
| 042 ## - AUTHENTICATION CODE |
|---|
| Authentication code |
dc |
| 245 #0 - TITLE STATEMENT |
|---|
| Title |
Apheresis in Neurological Disorders |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Basel, Switzerland |
| Name of publisher, distributor, etc. |
MDPI - Multidisciplinary Digital Publishing Institute |
| Date of publication, distribution, etc. |
2020 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
1 electronic resource (174 p.) |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Apheresis refers to an extracorporeal therapy which aims at removing pathological constituents from the patients's 2019; blood. Due to the development of new techniques as well as the discovery of novel autoimmune antibodies, it is increasingly recognized as an important therapeutic option for a variety of autoimmune-mediated neurological disorders, including multiple sclerosis, myasthenia gravis, autoimmune encephalitis, Guillain's 2013;Barre syndrome, and many others. Therapeutic plasma exchange (TPE) constitutes the standard method of apheresis for most indications, while immunoadsorption (IA) offers a more specific, low-risk alternative. Both methods aim at removing auto-antibodies from the blood. Evidence for most neurological diseases is still low. Interestingly, more recent developments suggest that apheresis is not limited to the removal of autoantibodies but may also be useful in neurodegenerative and possibly even in acute vascular disorders. |
| 540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE |
|---|
| Terms governing use and reproduction |
Creative Commons |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
immunoadsorption |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Dorst, Johannes |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Dorst, Johannes |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="https://directory.doabooks.org/handle/20.500.12854/69367">https://directory.doabooks.org/handle/20.500.12854/69367</a> |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="https://mdpi.com/books/pdfview/book/3160">https://mdpi.com/books/pdfview/book/3160</a> |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="www.oapen.org">www.oapen.org</a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
E-Book |
